Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Longitudinal changes in HIV-1-specific T-cell quality associated with viral load dynamic.

Dembek CJ, Kutscher S, Allgayer S, Russo C, Bauer T, Hoffmann D, Goebel FD, Bogner JR, Erfle V, Protzer U, Cosma A.

J Clin Virol. 2012 Oct;55(2):114-20. doi: 10.1016/j.jcv.2012.06.017. Epub 2012 Jul 13.

PMID:
22795599
2.

Single-cell level response of HIV-specific and cytomegalovirus-specific CD4 T cells correlate with viral control in chronic HIV-1 subtype A infection.

Eller MA, Eller LA, Ratto-Kim S, Ouma BJ, Lo V, de Souza M, Guwatudde D, Nails B, Michael NL, Wabwire-Mangen F, Robb ML, Marovich MA, Sandberg JK, Currier JR.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):9-18. doi: 10.1097/QAI.0b013e31825c1217.

PMID:
22580564
3.

Human immunodeficiency virus type I-specific CD8+ T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy.

Pohling J, Zipperlen K, Hollett NA, Gallant ME, Grant MD.

BMC Infect Dis. 2010 May 25;10:129. doi: 10.1186/1471-2334-10-129.

4.

Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.

Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin AG, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C.

AIDS. 2005 Jan 3;19(1):25-33.

PMID:
15627030
6.

HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.

Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G.

Proc Natl Acad Sci U S A. 2005 May 17;102(20):7239-44. Epub 2005 May 4.

7.

IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression.

Bailer RT, Holloway A, Sun J, Margolick JB, Martin M, Kostman J, Montaner LJ.

J Immunol. 1999 Jun 15;162(12):7534-42.

8.

Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies.

Oxenius A, Price DA, Trkola A, Edwards C, Gostick E, Zhang HT, Easterbrook PJ, Tun T, Johnson A, Waters A, Holmes EC, Phillips RE.

J Infect Dis. 2004 Aug 15;190(4):713-21. Epub 2004 Jul 20.

PMID:
15272399
9.
10.

Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.

Nemes E, Lugli E, Nasi M, Ferraresi R, Pinti M, Bugarini R, Borghi V, Prati F, Esposito R, Cossarizza A, Mussini C.

AIDS. 2006 Oct 24;20(16):2021-32.

PMID:
17053348
11.

Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.

Jansen CA, De Cuyper IM, Steingrover R, Jurriaans S, Sankatsing SU, Prins JM, Lange JM, van Baarle D, Miedema F.

AIDS. 2005 Jul 22;19(11):1145-54.

PMID:
15990567
12.

Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.

Oxenius A, Price DA, Dawson SJ, Günthard HF, Fischer M, Perrin L, Ramirez E, Fagard C, Hirschel B, Scullard G, Weber JN, McLean AR, Phillips RE; Swiss HIV cohort study.

AIDS. 2002 Nov 22;16(17):2317-22.

PMID:
12441804
13.

Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.

López M, Soriano V, Rallón N, Cascajero A, González-Lahoz J, Benito JM.

Eur J Immunol. 2008 Jun;38(6):1548-58. doi: 10.1002/eji.200738054.

14.

HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.

Rallón NI, Soriano V, Restrepo C, García-Samaniego J, Labarga P, López M, Peris A, González-Lahoz J, Benito JM.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):1-8.

PMID:
21786458
15.

Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52. Epub 2002 Oct 7.

16.

Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.

Plana M, García F, Gallart T, Tortajada C, Soriano A, Palou E, Maleno MJ, Barceló JJ, Vidal C, Cruceta A, Miró JM, Gatell JM.

AIDS. 2000 Sep 8;14(13):1921-33.

PMID:
10997396
17.

Antiretroviral therapy-induced dominant interleukin-2 HIV-1 Gag CD4+ T cell response: evidence of functional recovery of HIV-1-specific CD4+ T cells.

Tsalimalma K, Kordossis T, Choremi-Papadopoulou E.

Scand J Immunol. 2011 Mar;73(3):256-65. doi: 10.1111/j.1365-3083.2010.02502.x.

18.

IFN-gamma and IL-12 differentially regulate CC-chemokine secretion and CCR5 expression in human T lymphocytes.

Losana G, Bovolenta C, Rigamonti L, Borghi I, Altare F, Jouanguy E, Forni G, Casanova JL, Sherry B, Mengozzi M, Trinchieri G, Poli G, Gerosa F, Novelli F.

J Leukoc Biol. 2002 Oct;72(4):735-42.

PMID:
12377943
19.

CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy.

Nicholson JK, Browning SW, Hengel RL, Lew E, Gallagher LE, Rimland D, McDougal JS.

J Acquir Immune Defic Syndr. 2001 Jun 1;27(2):105-15.

PMID:
11404531
20.

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.

Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, Negredo E, Sirera G, Tural C, Clotet B.

AIDS. 2000 Mar 10;14(4):397-403.

PMID:
10770542

Supplemental Content

Support Center